Recursion Pharmaceuticals (RXRX) Other Non-Current Liabilities (2024 - 2026)

Recursion Pharmaceuticals (RXRX) has 3 years of Other Non-Current Liabilities data on file, last reported at $2.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 57.72% year-over-year to $2.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.0 million (down 57.72% YoY), and the FY2025 full-year result was $2.1 million, down 56.04% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $2.0 million, down from $2.1 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $4.8 million in Q1 2025 and bottomed at $1.0 million in Q3 2025.
• The 3-year median for Other Non-Current Liabilities is $2.5 million (2024), against an average of $2.8 million.
• Peak annual rise in Other Non-Current Liabilities reached 47.83% in 2025, while the deepest fall reached 65.69% in 2025.
• A 3-year view of Other Non-Current Liabilities shows it stood at $4.7 million in 2024, then tumbled by 56.04% to $2.1 million in 2025, then retreated by 2.64% to $2.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $2.0 million (Q1 2026), $2.1 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.

Peer Comparison